KingMed Diagnostics

KingMed Diagnostics Group Co., Ltd. [Stock Code: 603882] is a high-tech service enterprise that focuses on third-party medical testing and pathology diagnosis services. By continuously accumulating core resource advantages such as "large platforms, extensive networks, comprehensive services, vast sample repositories, and big data," it is committed to providing leading medical diagnostic information integration services to medical institutions at all levels across China. The core entrepreneurial team of KingMed Diagnostics has been actively exploring the operational model of medical testing outsourcing services in China since the 1990s, pioneering the domestic third-party medical testing industry. After years of development, it has become the market leader in China's third-party medical testing industry. Adhering strictly to international standards, KingMed Diagnostics has established an advanced quality management system and obtained 68 certification and accreditation certificates from authoritative domestic and international organizations, including the American CAP, China CNAS, and France BV, leading the industry for 21 consecutive years. Through independent innovation, industry-university-research collaborative innovation, and open innovation, KingMed Diagnostics offers over 3,800 medical testing and pathology diagnostic projects, with test results recognized in more than 70 countries and regions worldwide. KingMed Diagnostics has established 49 medical laboratories in mainland China and the Hong Kong and Macao regions, over 750 cooperative co-built laboratories, and a nationwide telepathology collaboration network. With a focus on clinical needs and disease-oriented solutions, it provides medical testing and pathology diagnostic services characterized by "full life-cycle coverage, full disease spectrum inclusion, and comprehensive diagnostic management" to more than 23,000 medical institutions across China. Its service network covers over 90% of China’s population, extending high-quality medical testing services to township and community levels, actively meeting the precise testing needs of grassroots and even remote frontline clinical settings, making medical testing more accessible. The company emphasizes building an international team of top talents, with 1,200 R&D personnel and over 280 renowned experts from China and abroad. It has also established the KingMed Diagnostics Academic Committee, chaired by Academician Nanshan Zhong, with nine academician advisors—Runsheng Chen, Yeguang Chen, Hefeng Huang, Fanfan Hou, Xiaokun Li, Weihong Tan, Xiaoliang Xie, Xue Zhang, and Yitao Zeng—and comprising 57 top experts in testing, pathology, and clinical fields from China and overseas. KingMed Diagnostics possesses 82 types of medical testing technology platforms across eight major disciplines. The company has been recognized as a National High-Tech Enterprise, a National Demonstration Center for Gene Testing Technology Applications, a National Intellectual Property Demonstration Enterprise, and a National Public Technical Service Platform for Small and Medium Enterprises. It has been approved to establish a National-Local Joint Engineering Laboratory for Medical Testing Technology and Services, a national postdoctoral research workstation, a Guangdong Province Academician Workstation, and a Guangdong Province Key Enterprise Laboratory, among other national and provincial-level R&D institutions and platforms. In recent years, leveraging the world's largest biobank and database of Eastern populations, KingMed Diagnostics is comprehensively advancing its MedTest 4.0 strategy, accelerating the development and application of large samples and big data in clinical research, medical testing technology innovation, and artificial intelligence. It aims to build an open innovation platform and construct a smart medical testing innovation and industrial ecosystem, striving to become a leading provider of integrated medical diagnostic information services both domestically and internationally.